低剂量 olanzapine 治疗与癌症相关的厌食症和恶心:从临床实践的见解
Rituparna Biswas1,2, Krishnangshu Bhanja Choudhury1,3, Anirban Halder4,5
1Department of Radiation Oncology, Malda Medical College, Malda 732101, India.
Ecancermedicalscience
|March 4, 2026
概括
低剂量 olanzapine 有效地管理癌症厌食-缓解症综合征 (CACS) 和相关的恶心. 这种耐受性很好,具有成本效益的治疗方法显示出作为一线选择的前景,特别是在资源有限的环境中.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 代谢障碍 代谢障碍 代谢障碍
背景情况:
- 癌症厌食-缓解症综合征 (CACS) 是一种复杂的代谢状况,常见于晚期癌症.
- 目前的治疗方法,如巨醇和皮质类固醇,由于成本和副作用而存在局限性.
- 建议使用olanzapine治疗CACS,但实际数据有限.
研究的目的:
- 评估低剂量 olanzapine 在管理 CACS. 在现实世界的有效性和耐受性.
- 评估 olanzapine 对癌症患者的厌食症,体重和恶心的影响.
主要方法:
- 在印度的第三级瘤学中心进行了回顾性队列研究.
- 包括50名患有固体恶性瘤和严重厌食症的患者 (18-70岁).
- 患者在12周内每天接受2.5毫克 olanzapine.
主要成果:
- 82%的患者报告说,厌食症症状有所改善.
- 82%的体重保持或增加;16%的体重增加超过1公斤.
- 50%的耐火性恶心患者经历了缓解;没有报告任何不良事件.
结论:
- 低剂量 olanzapine (2.5 毫克/天) 是有效的,并在现实世界的设置中耐受好CACS管理.
- 这是一个成本高效的选择,在资源有限的环境中尤其有利.
- 奥兰沙平可以被认为是CACS的第一线药理干预.
相关概念视频
Treatment Resistant Cancers
2.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.7K
Psychosis: Goals of Pharmacotherapy
711
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
711
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
935
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
935
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
827
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
827
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
1.2K
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Phenothiazines, such as prochlorperazine...
1.2K
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
1.1K
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
Two synthetic agonists of THC,...
1.1K

